Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET

Company Participants

Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications

Fred Vogt – Interim President and Chief Executive Officer

Igor Bilinsky – Chief Operating Officer

Jim Ziegler – Executive Vice President-Commercial

Friedrich Finckenstein – Chief Medical Officer

Jean-Marc Bellemin – Chief Financial Officer

Raj Puri – Executive Vice President, Regulatory Strategy and Translational Medicine

Conference Call Participants

Peter Lawson – Barclays

Michael Yee – Jefferies

Tyler Van Buren – TD Cowen

Colleen Kusy – Baird

Yanan Zhu – Wells Fargo

Reni Benjamin – JMP Securities

Carolina Ibanez Ventoso – Stifel

Asthika Goonewardene – Truist Securities

Joe Catanzaro – Piper Sandler

Mara Goldstein – Mizuho

Kelsey Goodwin – Guggenheim

Operator

Welcome to the Iovance Biotherapeutics’ Second Quarter 2023 Financial Results and Corporate Update Conference Call. My name is Shannon and I will be your operator for today’s call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Please note that this conference is being recorded.

I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara you may begin.

Sara Pellegrino

Thank you, operator. Good afternoon and thank you for joining us.

Speaking on today’s call, we have Dr. Fred Vogt, our Interim President and Chief Executive Officer; Dr. Igor Bilinsky, our Chief Operating Officer; Jim Ziegler, our Executive Vice President, Commercial; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer. Dr. Brian Gastman, Executive Vice President, Medical Affairs; and Raj Puri, our Executive Vice President, Regulatory Strategy and Translational Medicine are avail available for the Q&A Session.

This afternoon, we issued a press release that can be found on our corporate website at iovance.com, which includes the financial results for the three and six months ended on June 30, 2023 as well as recent corporate updates.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, pre-commercial activities, clinical trials and results, regulatory interactions, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interactions, licenses and collaborations, cash position and expense guidance, and future updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time-to-time in our SEC filings.